Ocular immunology and inflammation · 2016
Interferon Alpha-2a Therapy in Patients with Refractory Behçet Uveitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hasanreisoglu Murat, Cubuk Mehmet Ozgur, Ozdek Sengul, Gurelik Gokhan, Aktas Zeynep, Hasanreisoglu Berati
Аннотация
PURPOSE: To report the results of IFNα2a therapy in patients with Behçet uveitis refractory to azathioprine-cyclosporine combination treatment.
METHODS: In a retrospective study, 39 patients treated with either azathioprine-cyclosporine combination treatment (group 1, n = 23) or IFNα2a (group 2, n = 16) with a diagnosis of ocular Behçet disease (BD), were included in the study. Group 2 consisted of patients who did not respond to conventional combination therapy, and were therefore treated with IFNα2a. Clinical response and relapse rates were recorded for each group.
RESULTS: The mean number of uveitis attacks/year per patient was 0.8 ± 1.6 in Group 1. In Group 2, a significant decrease in the mean number of uveitis attacks/year per patient was observed after initiation of IFNα2a (2.4 ± 1.8 vs 1.3 ± 2.0) (p<0.05). When the two groups were compared after administration of IFNα2a therapy, no statistical difference was found in terms of uveitis attack/year and attack-free intervals, with a partial response to both treatments.
CONCLUSIONS: IFNα2a therapy is an effective alternative for Behçet uveitis patients where conventional combination therapy fails.
METHODS: In a retrospective study, 39 patients treated with either azathioprine-cyclosporine combination treatment (group 1, n = 23) or IFNα2a (group 2, n = 16) with a diagnosis of ocular Behçet disease (BD), were included in the study. Group 2 consisted of patients who did not respond to conventional combination therapy, and were therefore treated with IFNα2a. Clinical response and relapse rates were recorded for each group.
RESULTS: The mean number of uveitis attacks/year per patient was 0.8 ± 1.6 in Group 1. In Group 2, a significant decrease in the mean number of uveitis attacks/year per patient was observed after initiation of IFNα2a (2.4 ± 1.8 vs 1.3 ± 2.0) (p<0.05). When the two groups were compared after administration of IFNα2a therapy, no statistical difference was found in terms of uveitis attack/year and attack-free intervals, with a partial response to both treatments.
CONCLUSIONS: IFNα2a therapy is an effective alternative for Behçet uveitis patients where conventional combination therapy fails.
Предметные рубрики MeSH
AdolescentAdultAzathioprineBehcet SyndromeChildCyclosporineDrug CombinationsDrug ResistanceFemaleFluorescein AngiographyHumansImmunologic FactorsImmunosuppressive AgentsInterferon alpha-2Interferon-alphaMaleMiddle AgedRecombinant ProteinsRetrospective StudiesTomography, Optical CoherenceUveitisVisual Acuity